Lozenges, powders, chewable or effervescent versions should be considered, says Hermes Pharma
Up to 55% of consumers express some difficulty in swallowing tablets or capsules—the most common form of drug ingestions—according to a survey sponsored by Hermes Pharma (Pullach, Germany), a company that develops oral-solid formulations. While the study sponsor’s interest is obvious, it commissioned a third-party surveying firm, Spiegel Institut Mannheim, to conduct the poll of 1,000 US and German consumers, balanced for demographics. The survey did not distringuish between prescription and OTC products.
According to Hermes, younger adults (16-34 years) expressed even more dissatisfaction with oral solids than the elderly (65 or older), by a 70%-44% margin—a surprising result, given the difficulty that some seniors have with swallowing. Instant drinks and chewable tablets were preferred formulations for parents tending to their children’s needs. Additionally, upwards of 8% of patients say that difficulties in swallowing pills or capsules affects their adherence to therapy.
Hermes‘ conclusions:
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
New UK Consortium Obtains $1.34M Grant to Launch Automated Cell Therapy Manufacturing Platform
July 15th 2025Cellular Origins, CGT Catapult, and Resolution Therapeutics partner up to design a fully automated, scalable CGT manufacturing solution, with the goal of accelerating patient access to cell therapies.
Study Connects COVID-19 Treatment Disparities to Gaps in Testing and Virtual Access
July 11th 2025New research finds that nearly half of the racial and ethnic disparities in outpatient COVID-19 antiviral prescriptions stem from encounter-level care barriers, such as limited access to rapid tests and telehealth, which emphasizes the need for systemic and practice-level reforms.